日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Targeting de novo pyrimidine synthesis confers vulnerability to copper-mediated ATR inactivation in PARP inhibitor-resistant ovarian cancer.

靶向从头嘧啶合成会使 PARP 抑制剂耐药的卵巢癌对铜介导的 ATR 失活变得脆弱。

Nan Yabing, Wang Kunyu, Hu Menghan, Luo Qingyu, Wu Xiaowei, Yu Xiao, Zhou Xuantong, Chen Li, Li Bin, Cui Zhumei, Liu Zhihua

Lysine vitcylation is a vitamin C-derived protein modification that enhances STAT1-mediated immune response.

赖氨酸维生素C化是一种维生素C衍生的蛋白质修饰,可增强STAT1介导的免疫反应

He Xiadi, Wang Qiwei, Cheng Xin, Wang Weihua, Li Yutong, Nan Yabing, Wu Jiang, Xiu Bingqiu, Jiang Tao, Bergholz Johann S, Gu Hao, Chen Fuhui, Fan Guangjian, Sun Lianhui, Xie Shaozhen, Zou Junjie, Lin Sheng, Wei Yun, Lee James, Asara John M, Zhang Ke, Cantley Lewis C, Zhao Jean J

IRG1/itaconate/NRF2/GSH axis in tumor-associated macrophages drives therapy resistance and immune evasion in BRCA1-deficient breast cancer.

肿瘤相关巨噬细胞中的 IRG1/衣康酸/NRF2/GSH 轴驱动 BRCA1 缺陷型乳腺癌的治疗耐药性和免疫逃逸。

Nan Yabing, O'keefe Sophie, He Xiadi, Luo Qingyu, Wu Xiaowei, Ni Jing, Zou Yutian, Meade Jerryd Marcus, Li Yutong, Ji Renlei, Mohammad Anwaruddin, Kumar Pankaj, Wang Qiwei, Zhao Jean J

OTUB2 silencing promotes ovarian cancer via mitochondrial metabolic reprogramming and can be synthetically targeted by CA9 inhibition.

OTUB2 沉默通过线粒体代谢重编程促进卵巢癌的发生,并且可以通过 CA9 抑制剂进行合成靶向治疗

Nan Yabing, Wu Xiaowei, Luo Qingyu, Chang Wan, Zhao Pengfei, Zhang Lingqiang, Liu Zhihua